Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://hensel-electric.de](https://www.archivebay.com/archive6/images/0db7dab5-e954-4564-b0de-4569ad69fc37.png)
A complete backup of https://hensel-electric.de
Are you over 18 and want to see adult content?
![A complete backup of https://hospitalsafetyscore.org](https://www.archivebay.com/archive6/images/80419a38-cbe5-4cd6-a062-510ae2e8c2a5.png)
A complete backup of https://hospitalsafetyscore.org
Are you over 18 and want to see adult content?
![A complete backup of https://coventryobserver.co.uk](https://www.archivebay.com/archive6/images/02b1e7f3-8aee-48b7-98d1-77190a96381d.png)
A complete backup of https://coventryobserver.co.uk
Are you over 18 and want to see adult content?
![A complete backup of https://gls-group.eu](https://www.archivebay.com/archive6/images/b50b7872-9f4c-487c-853a-602cea58577d.png)
A complete backup of https://gls-group.eu
Are you over 18 and want to see adult content?
![A complete backup of https://hartberg.at](https://www.archivebay.com/archive6/images/cbd2825e-94eb-4d16-a61a-74bf99012a89.png)
A complete backup of https://hartberg.at
Are you over 18 and want to see adult content?
![A complete backup of https://climatecare.org](https://www.archivebay.com/archive6/images/eddd7965-8782-422d-936a-706798a2bbd4.png)
A complete backup of https://climatecare.org
Are you over 18 and want to see adult content?
![A complete backup of https://mesmac.co.uk](https://www.archivebay.com/archive6/images/c8a992df-b1a7-4fcf-a96e-1a84a2679ae8.png)
A complete backup of https://mesmac.co.uk
Are you over 18 and want to see adult content?
![A complete backup of https://williz.info](https://www.archivebay.com/archive6/images/5385a501-308a-4319-bd52-7e13ccc09e72.png)
A complete backup of https://williz.info
Are you over 18 and want to see adult content?
![A complete backup of https://braille-house.com](https://www.archivebay.com/archive6/images/ef7b9215-8384-4c12-b15d-36295013a55b.png)
A complete backup of https://braille-house.com
Are you over 18 and want to see adult content?
![A complete backup of https://blued.com](https://www.archivebay.com/archive6/images/2ab61092-9d61-42d6-a048-bb4ad1e8a415.png)
A complete backup of https://blued.com
Are you over 18 and want to see adult content?
![A complete backup of https://gulfresearchinitiative.org](https://www.archivebay.com/archive6/images/f9a38040-bf72-4753-b4f4-a57e939b89bd.png)
A complete backup of https://gulfresearchinitiative.org
Are you over 18 and want to see adult content?
![A complete backup of https://ilcerchiochedanza.com](https://www.archivebay.com/archive6/images/253603a9-bb9b-41a2-85e0-33d2e8d3e831.png)
A complete backup of https://ilcerchiochedanza.com
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of https://www.anime-planet.com/anime/watch-online/](https://www.archivebay.com/archive6/images/e3095725-1e41-4339-a392-8f27a52a68f0.png)
A complete backup of https://www.anime-planet.com/anime/watch-online/
Are you over 18 and want to see adult content?
![A complete backup of https://www.darknight.blog/%e7%84%a6%e8%ba%81/](https://www.archivebay.com/archive6/images/892601ad-2fee-410e-9518-2b15561e322e.png)
A complete backup of https://www.darknight.blog/%e7%84%a6%e8%ba%81/
Are you over 18 and want to see adult content?
![A complete backup of https://webslon.info/www/wefbee.net](https://www.archivebay.com/archive6/images/1200cc59-a893-448f-87c6-7392b04e242a.png)
A complete backup of https://webslon.info/www/wefbee.net
Are you over 18 and want to see adult content?
![A complete backup of https://www.blogger.com/profile/18346372048363891701](https://www.archivebay.com/archive6/images/b15bc3aa-daf0-4a2d-8e02-06ccdd0a13c0.png)
A complete backup of https://www.blogger.com/profile/18346372048363891701
Are you over 18 and want to see adult content?
![A complete backup of https://edebiyyat.az/](https://www.archivebay.com/archive6/images/25d2a489-e243-4572-a075-d9ed31eeac05.png)
A complete backup of https://edebiyyat.az/
Are you over 18 and want to see adult content?
Text
BRACELET-1
ONCOLYTICS BIOTECH® REPORTS 2021 FIRST QUARTER DEVELOPMENT "Our continued progress over the past several months has substantially de-risked our lead breast cancer program and validated our broader development strategy," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "Clinical data from our AWARE-1 trial show pelareorep alters tumor microenvironments by enabling the infiltration of anti-cancer T cells, shown to BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. ONCOLYTICS BIOTECH® ANNOUNCES UPCOMING PRESENTATION AT THE SAN DIEGO and CALGARY, AB, April 29, 2021 /CNW/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021. Details on the abstract and a corresponding poster presentation are PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T ONCOLYTICS BIOTECH® ANNOUNCES ASCO ABSTRACTS AND CALGARY, May 17, 2017 /PRNewswire/ - Oncolytics Biotech ® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the publication of abstracts for an open-label phase 1b trial in patients with metastatic adenocarcinoma of the pancreas (MAP) (REO 024) and an open-label, randomized, phase 2 study in metastatic castration resistant prostate cancer (mCRPC). ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Innately Adaptive™ Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY) Programs Combination Indication Preclinical Phase 1; Breast Cancer.BRACELET-1
ONCOLYTICS BIOTECH® REPORTS 2021 FIRST QUARTER DEVELOPMENT "Our continued progress over the past several months has substantially de-risked our lead breast cancer program and validated our broader development strategy," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "Clinical data from our AWARE-1 trial show pelareorep alters tumor microenvironments by enabling the infiltration of anti-cancer T cells, shown to BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. ONCOLYTICS BIOTECH® ANNOUNCES UPCOMING PRESENTATION AT THE SAN DIEGO and CALGARY, AB, April 29, 2021 /CNW/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021. Details on the abstract and a corresponding poster presentation are PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T ONCOLYTICS BIOTECH® ANNOUNCES ASCO ABSTRACTS AND CALGARY, May 17, 2017 /PRNewswire/ - Oncolytics Biotech ® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the publication of abstracts for an open-label phase 1b trial in patients with metastatic adenocarcinoma of the pancreas (MAP) (REO 024) and an open-label, randomized, phase 2 study in metastatic castration resistant prostate cancer (mCRPC). ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Developing Potential Treatments for a Variety of Tumor Types. Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. CONTACT :: ONCOLYTICS BIOTECH, INC. (ONCY) San Diego, California 4660 La Jolla Village Dr. Ste. 850 San Diego, CA92122
CAREERS :: ONCOLYTICS BIOTECH, INC. (ONCY) Join Our Team. Oncolytics is always looking for motivated, ambitious, talented and passionate professionals to join our team. We offer a competitive benefits package that caters to your country of residence(U.S. or Canada).
CLINICAL DEVELOPMENT PLAN :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics is currently focused on immunotherapy combinations, including our studies with Bavencio ®, Keytruda ®, Opdivo ®, Tecentriq ®, and Retifanlimab.. Our clinical development plan is based on pelareorep’s broad applicability to boost the effectiveness of a range of immunotherapies – with an immediate focus on checkpoint inhibitors – across multiple cancer indications. ONCOLYTICS BIOTECH® DOSES FIRST PATIENT IN PHASE 2 The randomized BRACELET-1 study is designed to support the results of a prior successful phase 2 trial that showed a near doubling of overall survival with pelareorep treatment, by demonstrating pelareorep's ability to induce a robust anti-tumor immune response in an identical patient population (patients with HR+/HER2- mBC).The ability of pelareorep-induced immune responses to enhance anti PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T WHAT DOES PELAREOREP DO? :: ONCOLYTICS BIOTECH, INC. (ONCY) Immunotherapy is a therapy in which certain parts of the immune system are used to treat a disease by enhancing, inducing or suppressing animmune response.
EVENTS & PRESENTATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) 2021 Annual General Meeting & First Quarter 2021 Financial ResultsConference Call
ONCOLYTICS BIOTECH(R) ANNOUNCES EXERCISE OF WARRANTS SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the exercise of warrants from it's August 2019 financing.. The Company announced the exercise of approximately 1.4 million warrants, at an exercise price of USD $0.90, for ONCOLYTICS BIOTECH® INC. AND ADLAI NORTYE ENTER INTO USD Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21.2 million, and eligible to receive up to an additional USD $65.4 million upon achievement of clinical, regulatory and commercializationmilestones
ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Innately Adaptive™ Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate andadaptive immune
ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY) FPI Expected H1 2021. NU 18I01. Pancreatic Cancer. Preclinical Phase complete. Phase 1 Phase complete. Phase 2 Phase in progress. Phase 3 Phase not started. Phase 2 NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. CLINICAL DEVELOPMENT PLAN :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics is currently focused on immunotherapy combinations, including our studies with Bavencio ®, Keytruda ®, Opdivo ®, Tecentriq ®, and Retifanlimab.. Our clinical development plan is based on pelareorep’s broad applicability to boost the effectiveness of a range of immunotherapies – with an immediate focus on checkpoint inhibitors – across multiple cancer indications. PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T SNAPSHOT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech, Inc. Nasdaq: ONCY. Price ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Innately Adaptive™ Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate andadaptive immune
ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY) FPI Expected H1 2021. NU 18I01. Pancreatic Cancer. Preclinical Phase complete. Phase 1 Phase complete. Phase 2 Phase in progress. Phase 3 Phase not started. Phase 2 NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. CLINICAL DEVELOPMENT PLAN :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics is currently focused on immunotherapy combinations, including our studies with Bavencio ®, Keytruda ®, Opdivo ®, Tecentriq ®, and Retifanlimab.. Our clinical development plan is based on pelareorep’s broad applicability to boost the effectiveness of a range of immunotherapies – with an immediate focus on checkpoint inhibitors – across multiple cancer indications. PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T SNAPSHOT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech, Inc. Nasdaq: ONCY. Price ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
CLINICAL DEVELOPMENT PLAN :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics is currently focused on immunotherapy combinations, including our studies with Bavencio ®, Keytruda ®, Opdivo ®, Tecentriq ®, and Retifanlimab.. Our clinical development plan is based on pelareorep’s broad applicability to boost the effectiveness of a range of immunotherapies – with an immediate focus on checkpoint inhibitors – across multiple cancer indications. CAREERS :: ONCOLYTICS BIOTECH, INC. (ONCY) Join Our Team. Oncolytics is always looking for motivated, ambitious, talented and passionate professionals to join our team. We offer a competitive benefits package that caters to your country of residence(U.S. or Canada).
MANAGEMENT TEAM :: ONCOLYTICS BIOTECH, INC. (ONCY) Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences. She is an accomplished equestrian and spends her spare time on horseback. REPORTS :: ONCOLYTICS BIOTECH, INC. (ONCY) Fiscal Year Ended Dec 31, 2020. PDF . Management Information Circular POSTERS & PUBLICATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Abstract 1932. “Combination Therapy with Oncolytic Viruses and CAR T Cells” Kottke et al, Previously presented at CAR-TCR Summit Europe 2021. “A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027,AWARE-1)”.
WHAT DOES PELAREOREP DO? :: ONCOLYTICS BIOTECH, INC. (ONCY) Pelareorep is a true immuno-oncology agent that, in addition to causing tumor cell lysis, generates innate and adaptive anti-tumor immune responses. Pelareorep is a potential treatment for FAQS :: ONCOLYTICS BIOTECH, INC. (ONCY) For general inquiries, you may contact Oncolytics at (403) 670-7377 or info@oncolyticsbiotech.com. EVENTS & PRESENTATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) KOL Event: Emerging Role of Biomarkers and Oncolytic Viruses in the Treatment of Cancer. Presentation. April 9 – April 10, 2019. Needham & Company’s 18th Annual Healthcare Conference. March 30 – April 3, 2019. American Association for Cancer Research. March 8, 2019. 2018 Q4 Year End Results & Highlights Conference Call. February 11, 2019. ONCOLYTICS BIOTECH® INC. AND ADLAI NORTYE ENTER INTO USD Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21.2 million, and eligible to receive up to an additional USD $65.4 million upon achievement of clinical, regulatory and commercializationmilestones
ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat avariety of solid
TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate andadaptive immune
ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor. Oct 19, 2020. PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY) FPI Expected H1 2021. NU 18I01. Pancreatic Cancer. Preclinical Phase complete. Phase 1 Phase complete. Phase 2 Phase in progress. Phase 3 Phase not started. Phase 2 BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
ONCOLYTICS BIOTECH® ANNOUNCES STATISTICALLY SIGNIFICANT SAN DIEGO and CALGARY, Alberta, Jan. 27, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a poster presentation highlighting statistically significant data identifying CEACAM6 as a prospective biomarker for pelareorep in the treatment of pancreatic cancer. PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T ONCOLYTICS BIOTECH(R) ANNOUNCES EXERCISE OF WARRANTS The Company announced the exercise of approximately 1.4 million warrants, at an exercise price of USD $0.90, for net proceeds of approximately USD $1,250,000. "We are very happy to see these warrants exercised so early," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. "This speaks not only to our rapid appreciation asof late
ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Innately Adaptive™ Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate andadaptive immune
ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY) FPI Expected H1 2021. NU 18I01. Pancreatic Cancer. Preclinical Phase complete. Phase 1 Phase complete. Phase 2 Phase in progress. Phase 3 Phase not started. Phase 2 NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor. Oct 19, 2020. BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
ONCOLYTICS BIOTECH® ANNOUNCES STATISTICALLY SIGNIFICANT SAN DIEGO and CALGARY, Alberta, Jan. 27, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a poster presentation highlighting statistically significant data identifying CEACAM6 as a prospective biomarker for pelareorep in the treatment of pancreatic cancer. PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T ONCOLYTICS BIOTECH(R) ANNOUNCES EXERCISE OF WARRANTS The Company announced the exercise of approximately 1.4 million warrants, at an exercise price of USD $0.90, for net proceeds of approximately USD $1,250,000. "We are very happy to see these warrants exercised so early," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. "This speaks not only to our rapid appreciation asof late
NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor. Oct 19, 2020. ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T DELIVERY :: ONCOLYTICS BIOTECH, INC. (ONCY) Delivery. Following systemic intravenous delivery, where pelareorep has demonstrated the ability to escape neutralizing antibodies found in patients, it binds to peripheral blood mononuclear cells (PBMCs), mainly natural killer cells and dendritic cells. NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor ONCOLYTICS BIOTECH® REPORTS 2020 THIRD QUARTER DEVELOPMENT "We continue to execute on our clinical and corporate milestones to expand the understanding and clinical benefit of pelareorep," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "Clinical AWARE-1 data presented at SITC 2020 demonstrated the ability of pelareorep to reverse immunosuppressive tumor microenvironments and generate the anti-tumor T cell clones ONCOLYTICS BIOTECH® ANNOUNCES ANNUAL GENERAL MEETING Management will also provide its annual corporate update after the conclusion of the meeting. SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), (the "Company") today announced that its upcoming 2021 Annual General Meeting (the "Meeting") will be held virtually at 12:00 p.m. Eastern Daylight Time (ET) on Friday, May 7, 2021. FAQS :: ONCOLYTICS BIOTECH, INC. (ONCY) For general inquiries, you may contact Oncolytics at (403) 670-7377 or info@oncolyticsbiotech.com. ONCOLYTICS BIOTECH® INC. AND ADLAI NORTYE ENTER INTO USD Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21.2 million, and eligible to receive up to an additional USD $65.4 million upon achievement of clinical, regulatory and commercializationmilestones
ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat avariety of solid
TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate andadaptive immune
ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY) FPI Expected H1 2021. NU 18I01. Pancreatic Cancer. Preclinical Phase complete. Phase 1 Phase complete. Phase 2 Phase in progress. Phase 3 Phase not started. Phase 2 INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T ONCOLYTICS BIOTECH® ANNOUNCES STATISTICALLY SIGNIFICANT SAN DIEGO and CALGARY, Alberta, Jan. 27, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a poster presentation highlighting statistically significant data identifying CEACAM6 as a prospective biomarker for pelareorep in the treatment of pancreatic cancer. ONCOLYTICS BIOTECH® PRESENTS CLINICAL DATA SUPPORTING A SAN DIEGO and CALGARY, Alberta, May 26, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study. ONCOLYTICS BIOTECH(R) ANNOUNCES EXERCISE OF WARRANTS The Company announced the exercise of approximately 1.4 million warrants, at an exercise price of USD $0.90, for net proceeds of approximately USD $1,250,000. "We are very happy to see these warrants exercised so early," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. "This speaks not only to our rapid appreciation asof late
ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat avariety of solid
TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate andadaptive immune
ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY) FPI Expected H1 2021. NU 18I01. Pancreatic Cancer. Preclinical Phase complete. Phase 1 Phase complete. Phase 2 Phase in progress. Phase 3 Phase not started. Phase 2 INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T ONCOLYTICS BIOTECH® ANNOUNCES STATISTICALLY SIGNIFICANT SAN DIEGO and CALGARY, Alberta, Jan. 27, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a poster presentation highlighting statistically significant data identifying CEACAM6 as a prospective biomarker for pelareorep in the treatment of pancreatic cancer. ONCOLYTICS BIOTECH® PRESENTS CLINICAL DATA SUPPORTING A SAN DIEGO and CALGARY, Alberta, May 26, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study. ONCOLYTICS BIOTECH(R) ANNOUNCES EXERCISE OF WARRANTS The Company announced the exercise of approximately 1.4 million warrants, at an exercise price of USD $0.90, for net proceeds of approximately USD $1,250,000. "We are very happy to see these warrants exercised so early," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. "This speaks not only to our rapid appreciation asof late
ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T DELIVERY :: ONCOLYTICS BIOTECH, INC. (ONCY) Delivery. Following systemic intravenous delivery, where pelareorep has demonstrated the ability to escape neutralizing antibodies found in patients, it binds to peripheral blood mononuclear cells (PBMCs), mainly natural killer cells and dendritic cells. NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor ONCOLYTICS BIOTECH® ANNOUNCES ANNUAL GENERAL MEETING Management will also provide its annual corporate update after the conclusion of the meeting. SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), (the "Company") today announced that its upcoming 2021 Annual General Meeting (the "Meeting") will be held virtually at 12:00 p.m. Eastern Daylight Time (ET) on Friday, May 7, 2021. WHAT DOES PELAREOREP DO? :: ONCOLYTICS BIOTECH, INC. (ONCY) Pelareorep is a true immuno-oncology agent that, in addition to causing tumor cell lysis, generates innate and adaptive anti-tumor immune responses. Pelareorep is a potential treatment for ONCOLYTICS BIOTECH® ANNOUNCES VOTING RESULTS FROM THE SAN DIEGO and CALGARY, AB, May 10, 2021 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting of Shareholders held on Friday, May 7, 2021. A total of 41.41% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at themeeting.
ONCOLYTICS BIOTECH® INC. AND ADLAI NORTYE ENTER INTO USD Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21.2 million, and eligible to receive up to an additional USD $65.4 million upon achievement of clinical, regulatory and commercializationmilestones
ONCOLYTICS BIOTECH(R) PRESENTS POSITIVE REOLYSIN(R) DATA Oncolytics Biotech(R) Presents Positive REOLYSIN(R) Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018 ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Innately Adaptive™ Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate andadaptive immune
ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY)ONCOLYTICS BIOTECH INCONCOLYTICS BIOTECH MESSAGE BOARDONCOLYTICS BIOTECH NEWS FPI Expected H1 2021. NU 18I01. Pancreatic Cancer. Preclinical Phase complete. Phase 1 Phase complete. Phase 2 Phase in progress. Phase 3 Phase not started. Phase 2 INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. MANAGEMENT TEAM :: ONCOLYTICS BIOTECH, INC. (ONCY) Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences. She is an accomplished equestrian and spends her spare time on horseback. WHAT DOES PELAREOREP DO? :: ONCOLYTICS BIOTECH, INC. (ONCY) Pelareorep is a true immuno-oncology agent that, in addition to causing tumor cell lysis, generates innate and adaptive anti-tumor immune responses. Pelareorep is a potential treatment for PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Innately Adaptive™ Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate andadaptive immune
ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotypethrough
PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY)ONCOLYTICS BIOTECH INCONCOLYTICS BIOTECH MESSAGE BOARDONCOLYTICS BIOTECH NEWS FPI Expected H1 2021. NU 18I01. Pancreatic Cancer. Preclinical Phase complete. Phase 1 Phase complete. Phase 2 Phase in progress. Phase 3 Phase not started. Phase 2 INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Company Overview. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission andregistration in
NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. MANAGEMENT TEAM :: ONCOLYTICS BIOTECH, INC. (ONCY) Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences. She is an accomplished equestrian and spends her spare time on horseback. WHAT DOES PELAREOREP DO? :: ONCOLYTICS BIOTECH, INC. (ONCY) Pelareorep is a true immuno-oncology agent that, in addition to causing tumor cell lysis, generates innate and adaptive anti-tumor immune responses. Pelareorep is a potential treatment for PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech ® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T CONTACT :: ONCOLYTICS BIOTECH, INC. (ONCY) San Diego, California 4660 La Jolla Village Dr. Ste. 850 San Diego, CA92122
CAREERS :: ONCOLYTICS BIOTECH, INC. (ONCY) Join Our Team. Oncolytics is always looking for motivated, ambitious, talented and passionate professionals to join our team. We offer a competitive benefits package that caters to your country of residence(U.S. or Canada).
MANAGEMENT TEAM :: ONCOLYTICS BIOTECH, INC. (ONCY) Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences. She is an accomplished equestrian and spends her spare time on horseback. INSIGHTS :: ONCOLYTICS BIOTECH, INC. (ONCY) Insights. Welcome to Oncolytics Insights. Here we will provide commentary on recent news, presentations and happenings related to Oncolytics and our development programs. Sep 1, 2020. COLLABORATORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Merck. Oncolytics is combining pelareorep with Merck’s anti-PD-1, pembrolizumab (Keytruda ® ), in two Investigator Sponsored Trials (IST’s). The goal is to expand the use of checkpoint inhibitors as anti-cancer agents by promoting an inflamed phenotype in the tumor or turning cold tumors hot. The first study is in second line pancreatic CLINICAL DEVELOPMENT PLAN :: ONCOLYTICS BIOTECH, INC. (ONCY) Clinical Development Plan. Oncolytics is currently focused on immunotherapy combinations, including our studies with Bavencio ®, Keytruda ®, Opdivo ®, Tecentriq ®, and Retifanlimab. Our clinical development plan is based on pelareorep’s broad applicability to boost the effectiveness of a range of immunotherapies – with animmediate
DELIVERY :: ONCOLYTICS BIOTECH, INC. (ONCY) Delivery. Following systemic intravenous delivery, where pelareorep has demonstrated the ability to escape neutralizing antibodies found in patients, it binds to peripheral blood mononuclear cells (PBMCs), mainly natural killer cells and dendritic cells. WHAT DOES PELAREOREP DO? :: ONCOLYTICS BIOTECH, INC. (ONCY) Pelareorep is a true immuno-oncology agent that, in addition to causing tumor cell lysis, generates innate and adaptive anti-tumor immune responses. Pelareorep is a potential treatment for SNAPSHOT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech, Inc. Nasdaq: ONCY. Price ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Innately Adaptive™ Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Developing Potential Treatments for a Variety of Tumor Types. Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY)ONCOLYTICS BIOTECH INCONCOLYTICS BIOTECH MESSAGE BOARDONCOLYTICS BIOTECH NEWS Programs Combination Indication Preclinical Phase 1; Breast Cancer.BRACELET-1
BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY)ONCOLYTICS BIOTECH Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T WHAT DOES PELAREOREP DO? :: ONCOLYTICS BIOTECH, INC. (ONCY) Immunotherapy is a therapy in which certain parts of the immune system are used to treat a disease by enhancing, inducing or suppressing animmune response.
EVENTS & PRESENTATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) 2021 Annual General Meeting & First Quarter 2021 Financial ResultsConference Call
ONCOLYTICS BIOTECH, INC. (ONCY)NEWSABOUTTECHNOLOGYCLINICAL TRIALSINVESTORSCONTACT Innately Adaptive™ Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological TECHNOLOGY :: ONCOLYTICS BIOTECH, INC. (ONCY)CLINICAL TRIALSEVENTS & PRESENTATIONSBOARD OF DIRECTORSDELIVERYCONTACTABOUT What is Pelareorep. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. ABOUT :: ONCOLYTICS BIOTECH, INC. (ONCY) Developing Potential Treatments for a Variety of Tumor Types. Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T INVESTOR RELATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. PIPELINE :: ONCOLYTICS BIOTECH, INC. (ONCY)ONCOLYTICS BIOTECH INCONCOLYTICS BIOTECH MESSAGE BOARDONCOLYTICS BIOTECH NEWS Programs Combination Indication Preclinical Phase 1; Breast Cancer.BRACELET-1
BOARD OF DIRECTORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. PRESS RELEASES :: ONCOLYTICS BIOTECH, INC. (ONCY)ONCOLYTICS BIOTECH Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T WHAT DOES PELAREOREP DO? :: ONCOLYTICS BIOTECH, INC. (ONCY) Immunotherapy is a therapy in which certain parts of the immune system are used to treat a disease by enhancing, inducing or suppressing animmune response.
EVENTS & PRESENTATIONS :: ONCOLYTICS BIOTECH, INC. (ONCY) 2021 Annual General Meeting & First Quarter 2021 Financial ResultsConference Call
NEWS :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T CONTACT :: ONCOLYTICS BIOTECH, INC. (ONCY) San Diego, California 4660 La Jolla Village Dr. Ste. 850 San Diego, CA92122
CLINICAL DEVELOPMENT PLAN :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics is currently focused on immunotherapy combinations, including our studies with Bavencio ®, Keytruda ®, Opdivo ®, Tecentriq ®, and Retifanlimab.. Our clinical development plan is based on pelareorep’s broad applicability to boost the effectiveness of a range of immunotherapies – with an immediate focus on checkpoint inhibitors – across multiple cancer indications. CAREERS :: ONCOLYTICS BIOTECH, INC. (ONCY) Join Our Team. Oncolytics is always looking for motivated, ambitious, talented and passionate professionals to join our team. We offer a competitive benefits package that caters to your country of residence(U.S. or Canada).
MANUFACTURING :: ONCOLYTICS BIOTECH, INC. (ONCY) Manufacturing. Pelareorep is currently being manufactured at commercial scale in its final formulation under a commercial supply agreement with MilliporeSigma (formerly Sigma-Aldrich), the life science business of Merck KGaA. MANAGEMENT TEAM :: ONCOLYTICS BIOTECH, INC. (ONCY) Mr. Look is a Chartered Accountant with more than fifteen years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company's Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. COLLABORATORS :: ONCOLYTICS BIOTECH, INC. (ONCY) Based on the Company's Clinical Development Plan, Oncolytics is investigating potential partnerships for its phase 3 registration program in metastatic breast cancer (mBC), as well as additional collaborations with checkpoint inhibitors that will help advance pelareorep in different indications and disease states, including theadjuvant setting.
DELIVERY :: ONCOLYTICS BIOTECH, INC. (ONCY) Delivery. Following systemic intravenous delivery, where pelareorep has demonstrated the ability to escape neutralizing antibodies found in patients, it binds to peripheral blood mononuclear cells (PBMCs), mainly natural killer cells and dendritic cells. WHAT DOES PELAREOREP DO? :: ONCOLYTICS BIOTECH, INC. (ONCY) Immunotherapy is a therapy in which certain parts of the immune system are used to treat a disease by enhancing, inducing or suppressing animmune response.
SNAPSHOT :: ONCOLYTICS BIOTECH, INC. (ONCY) Oncolytics Biotech, Inc. Nasdaq: ONCY. Price* Home
* About
* Our Company
* Management Team
* Board of Directors* Technology
* What is Pelareorep? * What Does Pelareorep Do?* Delivery
* Intellectual Property * Posters & Publications* Manufacturing
* Clinical Trials
* Clinical Development Plan* Collaborators
* Pipeline
* Media
* Press Releases
* Insights
* Investors
* Overview
* Press Releases
* Events & Presentations* Stock Information
* Filings & Financials * Corporate Governance* FAQs
* Email Alerts
* IR Contacts
* Contact
* Careers
INNATELY ADAPTIVE™ Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies. CORPORATE PRESENTATION ONCOLYTICS: AN INVESTOR RELATIONS INTRODUCTIONLATEST NEWS
May 14, 2020
Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual MeetingMay 13, 2020
Oncolytics Biotech® to Present at the RBC Global HealthcareConference
May 8, 2020
Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational HighlightsView All News
OUR FOCUS: IMMUNOTHERAPY COMBINATIONS Oncolytics is currently focused on immunotherapy combinations, including our studies with Bavencio®, Keytruda®, Opdivo® andTecentriq®.
Cancers grow in our bodies because our immune systems do not recognize these tumors as foreign or as a threat. They do this by applying the brakes to our immune systems – notably T cells – through receptors called checkpoints. Immunotherapies, including checkpoint inhibitors, help our immune systems to recognize and kill cancer. Instead of attacking the tumor directly, checkpoint inhibitors work to prevent tumors from suppressing our immune systems. For some patients the effects are profound, BUT AS LOW AS 1-IN-5 PATIENTS WILL RESPOND TO CHECKPOINT BLOCKADE DEPENDING ON THE INDICATION. Responses are limited by when tumors do not have the key elements required for checkpoint blockade: * The presence of T cells* An inflamed tumor
* Expression of checkpoints Pelareorep has demonstrated the ability to create this tumor environment and conditions the tumor for multiple treatment combinations including checkpoint inhibitors and potentially other immuno-oncology drugs. Pelareorep creates a new army of tumor-reactive T cells, causes these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression of checkpoints, including PD-1/PD-L1. By priming the immune system before checkpoint blockade, we believe we can increase the percentage of patients who respond to checkpoint inhibitors and open up new indications where checkpoint blockade has been ineffective to date. This vast opportunity underlines the importance of our collaborations with Merck, Bristol-Myers Squibb, Roche and the Pfizer/Merck KGaA alliance in a variety of solid and hematological tumor targets. 2020 Oncolytics Biotech, Inc. All Rights Reserved. Privacy Policy Disclaimer SitemapDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0